- Home
- CGTX vs AKTX Comparison
CGTX vs AKTX Comparison
Compare CGTX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- AKTX
- Stock Information
- Founded
- CGTX 2007
- AKTX N/A
- Country
- CGTX United States
- AKTX United States
- Employees
- CGTX N/A
- AKTX N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- AKTX Health Care
- Exchange
- CGTX Nasdaq
- AKTX Nasdaq
- Market Cap
- CGTX 23.1M
- AKTX 29.1M
- IPO Year
- CGTX 2021
- AKTX N/A
- Fundamental
- Price
- CGTX $0.30
- AKTX $1.33
- Analyst Decision
- CGTX Strong Buy
- AKTX
- Analyst Count
- CGTX 5
- AKTX 0
- Target Price
- CGTX $6.13
- AKTX N/A
- AVG Volume (30 Days)
- CGTX 692.0K
- AKTX 31.7K
- Earning Date
- CGTX 05-07-2025
- AKTX 05-19-2025
- Dividend Yield
- CGTX N/A
- AKTX N/A
- EPS Growth
- CGTX N/A
- AKTX N/A
- EPS
- CGTX N/A
- AKTX N/A
- Revenue
- CGTX N/A
- AKTX N/A
- Revenue This Year
- CGTX N/A
- AKTX N/A
- Revenue Next Year
- CGTX N/A
- AKTX N/A
- P/E Ratio
- CGTX N/A
- AKTX N/A
- Revenue Growth
- CGTX N/A
- AKTX N/A
- 52 Week Low
- CGTX $0.31
- AKTX $0.85
- 52 Week High
- CGTX $2.95
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- CGTX 31.37
- AKTX 49.73
- Support Level
- CGTX $0.40
- AKTX $1.34
- Resistance Level
- CGTX $0.47
- AKTX $1.46
- Average True Range (ATR)
- CGTX 0.03
- AKTX 0.12
- MACD
- CGTX -0.01
- AKTX -0.01
- Stochastic Oscillator
- CGTX 2.76
- AKTX 31.25
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).